Number of Product Lines Acquired

No definition available.

Name:	cpix_NumberofProductLinesAcquired
Namespace Prefix:	cpix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	cpix_OtherRevenuesAbstract
Namespace Prefix:	cpix_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Product Commercialization Agreement, Number of Agreements

+ References

No definition available.

+ Details

Name:	cpix_ProductCommercializationAgreementNumberofAgreements
Namespace Prefix:	cpix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	cpix_ProductRevenuesAbstract
Namespace Prefix:	cpix_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Future Revenue Earned Upon Achieving MIlestone

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionMilestoneMethodFutureRevenueEarnedUponAchievingMilestone
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue Recognition, Potential Upfront Payment Related to Product Sales

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

+ Details

Name:	us-gaap_RevenueFromGrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cpix_AccruedLiabilitiesCurrentByComponentAxis=cpix_ProductSalesRelatedAccrualsRebatesProductReturnsAdministrativeFeesAndServiceFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_CaldolorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_ProductAcetadoteGenericMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=cpix_OutsideUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementLicensingAgreementWithHarbinGloriaPharmaceuticalsCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeOnApprovalOfAcetadoteAndCaldolorInChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_MilestoneMethodFutureRevenueReceiptOfRegulatoryNoticeRelatedToConductingClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenues (Narrative) (Details) (USD $)	12 Months Ended
Revenues (Narrative) (Details) (USD $)	Dec. 31, 2014 product_line	Dec. 31, 2013	Dec. 31, 2012
Revenue from External Customer [Line Items]
Number of product lines acquired	2cpix_NumberofProductLinesAcquired
Product Revenues [Abstract]
Net product revenue	$ 36,683,762us-gaap_SalesRevenueGoodsNet	$ 31,100,698us-gaap_SalesRevenueGoodsNet	$ 47,944,031us-gaap_SalesRevenueGoodsNet
Accrued liabilities, current	10,506,769us-gaap_AccruedLiabilitiesCurrent	5,509,917us-gaap_AccruedLiabilitiesCurrent
Other Revenues [Abstract]
Other revenues, milestone method	0
Product Sales Related Accruals - Rebates, Product Returns, Administrative Fees and Service Fees
Product Revenues [Abstract]
Accrued liabilities, current	5,200,000	2,400,000
Product, Omeclamox-Pak
Product Revenues [Abstract]
Net product revenue	4,111,916	1,045,815	0
Product, Caldolor
Product Revenues [Abstract]
Net product revenue	2,721,346	2,089,655	992,110
Product, Acetadote, Generic
Product Revenues [Abstract]
Net product revenue	5,800,000	9,200,000	300,000
Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods
Product Revenues [Abstract]
Accounts receivable, allowances, current	400,000	600,000
Collaborative Arrangement, Amended International Agreement
Other Revenues [Abstract]
Other revenue, agreements		6
Other revenues, milestone method		600,000
Other revenue, potential upfront payments related to regulatory approval		600,000
Other revenue, potential upfront payment related to product sales		4,000,000
Collaborative Arrangement, Federal Small Business Grant Programs
Other Revenues [Abstract]
Other revenues, grants	100,000	100,000	100,000
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd. \| Acetadote and Caldolor
Other Revenues [Abstract]
Other revenues, proceeds from sale of intangible assets			700,000
ERROR in label resolution. \| Acetadote and Caldolor
Other Revenues [Abstract]
Other revenues, milestone method, future revenue upon achieving milestones			700,000
ERROR in label resolution. \| Acetadote and Caldolor
Other Revenues [Abstract]
Other revenues, milestone method, future revenue upon achieving milestones			1,100,000
Outside US \| Product, Caldolor
Product Revenues [Abstract]
Net product revenue	$ 500,000